1. Home
  2. NTLA vs MSEX Comparison

NTLA vs MSEX Comparison

Compare NTLA & MSEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTLA
  • MSEX
  • Stock Information
  • Founded
  • NTLA 2014
  • MSEX 1897
  • Country
  • NTLA United States
  • MSEX United States
  • Employees
  • NTLA N/A
  • MSEX N/A
  • Industry
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • MSEX Water Supply
  • Sector
  • NTLA Health Care
  • MSEX Utilities
  • Exchange
  • NTLA Nasdaq
  • MSEX Nasdaq
  • Market Cap
  • NTLA 959.4M
  • MSEX 950.8M
  • IPO Year
  • NTLA 2016
  • MSEX N/A
  • Fundamental
  • Price
  • NTLA $10.70
  • MSEX $50.50
  • Analyst Decision
  • NTLA Buy
  • MSEX Sell
  • Analyst Count
  • NTLA 18
  • MSEX 2
  • Target Price
  • NTLA $50.53
  • MSEX $58.50
  • AVG Volume (30 Days)
  • NTLA 2.8M
  • MSEX 96.3K
  • Earning Date
  • NTLA 02-28-2025
  • MSEX 02-28-2025
  • Dividend Yield
  • NTLA N/A
  • MSEX 2.69%
  • EPS Growth
  • NTLA N/A
  • MSEX 24.58
  • EPS
  • NTLA N/A
  • MSEX 2.30
  • Revenue
  • NTLA $43,086,000.00
  • MSEX $183,372,000.00
  • Revenue This Year
  • NTLA $50.68
  • MSEX $14.26
  • Revenue Next Year
  • NTLA N/A
  • MSEX $6.01
  • P/E Ratio
  • NTLA N/A
  • MSEX $21.95
  • Revenue Growth
  • NTLA N/A
  • MSEX 10.14
  • 52 Week Low
  • NTLA $8.96
  • MSEX $45.42
  • 52 Week High
  • NTLA $34.87
  • MSEX $70.73
  • Technical
  • Relative Strength Index (RSI)
  • NTLA 51.96
  • MSEX 45.49
  • Support Level
  • NTLA $8.96
  • MSEX $48.66
  • Resistance Level
  • NTLA $10.73
  • MSEX $50.66
  • Average True Range (ATR)
  • NTLA 0.61
  • MSEX 1.19
  • MACD
  • NTLA 0.12
  • MSEX 0.29
  • Stochastic Oscillator
  • NTLA 88.32
  • MSEX 51.69

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About MSEX Middlesex Water Company

Middlesex Water Co owns and operates regulated water utility and wastewater systems in the U.S. The firm primarily operates in the eastern states of New Jersey, Delaware, and Pennsylvania. The company has two operating segments, Regulated and Non-Regulated. The regulated business includes collecting and distributing water to residential, commercial, industrial, and fire protection consumers. The non-regulated business includes contract services for the operation of private water and wastewater systems. The majority of the company's revenue is derived from the Regulated segment and from residential customers.

Share on Social Networks: